JP2002524520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524520A5 JP2002524520A5 JP2000569817A JP2000569817A JP2002524520A5 JP 2002524520 A5 JP2002524520 A5 JP 2002524520A5 JP 2000569817 A JP2000569817 A JP 2000569817A JP 2000569817 A JP2000569817 A JP 2000569817A JP 2002524520 A5 JP2002524520 A5 JP 2002524520A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- alprostadil
- phentolamine mesylate
- papaverine hydrochloride
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 26
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 11
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical group N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 11
- 229960000711 alprostadil Drugs 0.000 description 11
- 229960003056 phentolamine mesylate Drugs 0.000 description 11
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 11
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical group Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 10
- 229960003207 papaverine hydrochloride Drugs 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/154,677 US6482426B1 (en) | 1998-09-17 | 1998-09-17 | Compositions for the treatment of male erectile dysfunction |
| US09/154,677 | 1998-09-17 | ||
| PCT/US1999/021513 WO2000015233A1 (en) | 1998-09-17 | 1999-09-17 | Compositions for the treatment of male erectile dysfunction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002524520A JP2002524520A (ja) | 2002-08-06 |
| JP2002524520A5 true JP2002524520A5 (enExample) | 2006-11-02 |
| JP4721517B2 JP4721517B2 (ja) | 2011-07-13 |
Family
ID=22552291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000569817A Expired - Fee Related JP4721517B2 (ja) | 1998-09-17 | 1999-09-17 | 雄性勃起不全の処置のための組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6482426B1 (enExample) |
| EP (1) | EP1112075B1 (enExample) |
| JP (1) | JP4721517B2 (enExample) |
| CN (1) | CN1338939B (enExample) |
| AT (1) | ATE338554T1 (enExample) |
| AU (1) | AU772922B2 (enExample) |
| CA (1) | CA2344435C (enExample) |
| DE (1) | DE69933128T2 (enExample) |
| DK (1) | DK1112075T3 (enExample) |
| ES (1) | ES2273509T3 (enExample) |
| PT (1) | PT1112075E (enExample) |
| WO (1) | WO2000015233A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
| US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
| US6476037B1 (en) | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
| CN1315504A (zh) * | 2000-03-24 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人磷酸核糖甘氨酰胺合成酶12和编码这种多肽的多核苷酸 |
| DK1280531T3 (da) * | 2000-05-12 | 2007-05-29 | Novalar Pharmaceuticals Inc | Formulering bestående af phentolaminmesylat og anvendelse heraf |
| GB2375303A (en) * | 2001-05-11 | 2002-11-13 | Medical Res Council | Method of inducing cervical ripening |
| DE10142418A1 (de) * | 2001-08-31 | 2003-04-03 | Molecular And Clinical Drug Re | Arzneimittel |
| AU2003247568B2 (en) * | 2002-06-20 | 2008-03-06 | Septodont Holding Sas | Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| US7037257B1 (en) * | 2002-08-22 | 2006-05-02 | Koenig J Frank | Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications |
| KR20040043996A (ko) * | 2002-11-20 | 2004-05-27 | 조나겐, 아이엔씨. | 남성 발기부전치료를 위한 개선된 조성물 |
| JP4615929B2 (ja) * | 2004-08-11 | 2011-01-19 | 久光製薬株式会社 | イオントフォレーシス装置 |
| US7608589B2 (en) * | 2005-07-25 | 2009-10-27 | Therimunex Pharmaceuticals, Inc. | Peptidyl diacylglycerides |
| US20090112197A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
| US7862598B2 (en) * | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US8642093B2 (en) * | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US20110190604A1 (en) * | 2006-12-22 | 2011-08-04 | Hyde Roderick A | Nitric oxide sensors and systems |
| US8221690B2 (en) * | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
| US20090110933A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices related to nitric oxide releasing materials |
| US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
| US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
| US8877508B2 (en) * | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
| US8349262B2 (en) * | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
| US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
| US20090112193A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices that utilize photolyzable nitric oxide donors |
| US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US20090259217A1 (en) * | 2008-04-09 | 2009-10-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems associated with delivery of one or more agents to an individual |
| US20090259214A1 (en) * | 2008-04-09 | 2009-10-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Agent delivery device |
| WO2010070617A1 (en) * | 2008-12-19 | 2010-06-24 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
| AU2010363656C1 (en) * | 2010-11-12 | 2015-07-30 | Colgate-Palmolive Company | Oral care product and methods of use and manufacture thereof |
| US8560453B2 (en) | 2011-06-30 | 2013-10-15 | Intel Corporation | Method and apparatus for dynamic, real-time ad insertion based on meta-data within a hardware based root of trust |
| US20130303566A1 (en) * | 2012-05-09 | 2013-11-14 | David W. Hill | Method for treating macular degeneration |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| WO2018220232A1 (en) * | 2017-06-02 | 2018-12-06 | Universite De Versailles-St Quentin En Yvelines | Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction |
| CN109820820B (zh) * | 2019-02-25 | 2021-12-21 | 浙江长典药物技术开发有限公司 | 一种前列地尔注射液及其制备方法 |
| CN110193011B (zh) * | 2019-06-19 | 2022-02-11 | 四川美大康华康药业有限公司 | 一种甲磺酸酚妥拉明注射液及其制备方法 |
| CN111789818B (zh) * | 2020-08-15 | 2022-02-22 | 山东北大高科华泰制药有限公司 | 注射用盐酸罂粟碱药物组合物及制备方法 |
| US12053479B2 (en) | 2020-10-22 | 2024-08-06 | Madera Pharm aceuticals, Inc. | Transdermal treatment for erectile dysfunction |
| CN113143868B (zh) * | 2021-03-03 | 2022-04-12 | 海南久常制药有限公司 | 一种注射用盐酸罂粟碱及其制备方法 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3943246A (en) | 1972-07-10 | 1976-03-09 | Sandoz Ltd. | Organic compounds |
| US4139617A (en) | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
| US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4746651A (en) * | 1983-11-01 | 1988-05-24 | Scripps Clinic And Research Foundation | Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives |
| US4530920A (en) | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
| US4885173A (en) | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
| US4863911A (en) | 1986-08-04 | 1989-09-05 | University Of Florida | Method for treating male sexual dysfunction |
| US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| US5059603A (en) | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
| WO1990015583A1 (fr) | 1989-06-16 | 1990-12-27 | Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Dispositif de traitement de la faiblesse sexuelle chez l'homme |
| FR2649613B1 (fr) | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
| US5079018A (en) | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
| US5236904A (en) | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
| US5270323A (en) | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| US5399581A (en) | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
| US5298261A (en) | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
| US5646181A (en) * | 1992-07-02 | 1997-07-08 | Research Foundation Of State University Of New York | Method and compositions for treating impotence |
| US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| DK172203B1 (da) * | 1996-03-11 | 1998-01-05 | Gitte Bjeldbak | Elskovsmiddel, der virker seksuelt ophidsende på brugeren |
| PT996447E (pt) * | 1997-05-19 | 2006-12-29 | Zonagen Inc | Terapia combinada para moldular a resposta sexual humana |
| US20020068365A1 (en) * | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
| US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
-
1998
- 1998-09-17 US US09/154,677 patent/US6482426B1/en not_active Expired - Lifetime
-
1999
- 1999-09-17 PT PT99946977T patent/PT1112075E/pt unknown
- 1999-09-17 DK DK99946977T patent/DK1112075T3/da active
- 1999-09-17 ES ES99946977T patent/ES2273509T3/es not_active Expired - Lifetime
- 1999-09-17 EP EP99946977A patent/EP1112075B1/en not_active Expired - Lifetime
- 1999-09-17 AU AU59270/99A patent/AU772922B2/en not_active Ceased
- 1999-09-17 AT AT99946977T patent/ATE338554T1/de active
- 1999-09-17 CA CA2344435A patent/CA2344435C/en not_active Expired - Fee Related
- 1999-09-17 WO PCT/US1999/021513 patent/WO2000015233A1/en not_active Ceased
- 1999-09-17 DE DE69933128T patent/DE69933128T2/de not_active Expired - Lifetime
- 1999-09-17 CN CN998132926A patent/CN1338939B/zh not_active Expired - Fee Related
- 1999-09-17 JP JP2000569817A patent/JP4721517B2/ja not_active Expired - Fee Related
-
2000
- 2000-01-31 US US09/494,627 patent/US6696072B1/en not_active Expired - Lifetime
-
2003
- 2003-11-03 US US10/700,274 patent/US7776899B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002524520A5 (enExample) | ||
| CA2344435A1 (en) | Compositions for the treatment of male erectile dysfunction | |
| US6156753A (en) | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | |
| US6127363A (en) | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction | |
| ES2260043T3 (es) | Combinacion sinergica de roflumilast y salmeterol. | |
| JP2005512995A5 (enExample) | ||
| US20080132517A1 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
| JO2555B1 (en) | Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent | |
| CA2344090A1 (en) | Compositions and methods for treating female sexual dysfunction | |
| WO2003045437A8 (en) | Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene | |
| JP2002515432A (ja) | Ｈｉｖおよび他のウイルス感染の治療用組成物 | |
| JP2002521468A5 (enExample) | ||
| US20090023766A1 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
| HUP0303877A2 (hu) | Imidazotriazinon-tartalmú készítmények nazális alkalmazásra | |
| EP1237538A2 (en) | An improved pharmaceutical composition for treating male erectile dysfunction | |
| CN116847874A (zh) | Dhodh抑制剂化合物在组合癌症疗法中的用途 | |
| EA200100869A1 (ru) | Кристаллическая форма эплеренона | |
| CO5271647A1 (es) | Metodo para prevenir la diarrea | |
| US20060269598A1 (en) | Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use | |
| CA2425445A1 (en) | Tetrapeptide stimulating functional activity of hepatocytes, pharmacological substance on its basis and the method of its application | |
| JP2003523385A5 (enExample) | ||
| RU2003106417A (ru) | Применение комбинации витаминов для лечения первичных головных болей | |
| US20060269597A1 (en) | Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions | |
| US20230165811A1 (en) | Method for treating symptoms of viral infections | |
| WO2004050019A3 (en) | Method and compositions for treating anxiety |